Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Universal CAR-T cells take aim at tough leukemia in kids and adults

NCT ID NCT07470073

Recruiting now Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Mar 15, 2026 · Last updated May 16, 2026 · Updated 6 times

Summary

This early-phase study tests a new "universal" CAR-T cell therapy (CT1190B) for people aged 12 to 75 with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatment. The therapy is designed to target two markers on cancer cells (CD19 and CD20) and does not use the patient's own cells, making it potentially available off-the-shelf. The main goals are to check safety, find the best dose, and see how well it controls the leukemia.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALL (ACUTE B-LYMPHOBLASTIC LEUKEMIA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ALL (ACUTE B-LYMPHOBLASTIC LEUKEMIA)